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CHAPTER 1 :  
 
BACKGROUND AND LITERATURE REVIEW 
 
Introduction 
Coronavirus (CoV) infections cause a number of human diseases ranging in severity from 
the common cold to severe acute respiratory syndrome (SARS). Middle East respiratory 
syndrome CoV (MERS-CoV) and severe acute respiratory syndrome CoV (SARS-CoV) 
demonstrate the continued capacity of zoonotic CoVs to cause severe human respiratory 
disease. The likelihood of future zoonotic CoV emergence coupled with a lack of 
effective therapeutics or vaccines emphasizes the need to understand mechanisms of CoV 
replication. CoVs have a positive-sense RNA genome that is translated into polyproteins 
that are processed by up to three encoded proteases. The chymotrypsin-like cysteine 
protease (nsp5, 3CLpro) is responsible for 11 distinct cleavages within the polyprotein. 
Nsp5 is required for coronavirus replication; thus, it is a key target for structure function 
studies and for viral inhibition. We propose a series of experiments designed to elucidate 
the mechanism of nsp5 activity in order to inform de novo inhibitor design. Data obtained 
from this study will (i) define the role of the novel third domain and interdomain loop of 
nsp5, which connects the catalytic fold to the third domain, during substrate selection and 
catalytic activity, and (ii) develop novel inhibitors of nsp5 that exploit the mechanism and 
functional targets of nsp5. Results from these studies will inform antiviral and vaccine 
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development. This work will may also result in the first experimentally demonstrated 
model of how nsp5 functions in cell culture infection. 
 
Coronavirus identification, emergence, and disease 
Coronaviruses (CoVs) are classified within the subfamily coronavirinae, within the 
family of coronaviridae and within the order of nidovirales. They are divided into three 
genera, alpha (α-CoV), beta (β-CoV), and gammacoronaviruses (γ-CoV), which 
correspond to the previous groupings of 1, 2, and 3, respectively (Figure 1.1) CoVs are 
positive strand RNA viruses that infect a wide range of species (Figure 1.2). Currently 
there are 6 known human coronaviruses (HCoVs) (Figure 1.1), which cause a broad 
range of disease in human hosts from the common cold to acute respiratory distress 
syndrome (ARDS). HCoV-NL63, an α-CoV, is believed to cause bronchiolitis in 
children while HCoV-HKU1, a β-CoV, is associated with chronic respiratory disease in 
the elderly (48). HCoV-OC43 and HCoV-229E, two other HCoVs are known to cause the 
common cold. While most HCoV symptoms are relatively mild, SARS-CoV and MERS-
CoV are emerging zoonotic pathogens associated with severe acute respiratory illness 
and mortality.  
Coronavirus infections pose significant human health risks as well as a huge 
economic burden. SARS-CoV putatively emerged into the human population from bats in 
the Guangdong province of China in November of 2002 (57). SARS-CoV spread 
throughout over twenty countries and caused a pandemic from 2002-2003. Of the roughly 
8100 people infected, 774 died, resulting in a 10% case to fatality ratio. More severe 
illness was observed in elderly patients, with fatality rates reaching near 50% for those 
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over 50 years of age (47), while children younger than 12 years of age suffered much 
more mild symptoms (55). It is estimated that the SARS-CoV pandemic cost the United 
States healthcare system $30 – 100 billion (57), however, the majority of costs related to 
pandemics occur in non-health sectors, making it difficult to estimate the economic 
impact. For example, the WHO estimates that international travel fell by 50 - 70% and 
hotel occupancy dropped by >60% during the SARS-CoV pandemic (57).  
MERS-CoV emerged in the human population putatively from close human 
contact to camels in Saudi Arabia in 2012. The case-fatality ratio has been around 40%, 
but it has proven much less transmissible than SARS-CoV, with 827 laboratory 
confirmed cases since emergence in 2012 and at least 287 deaths (41, 44, 46). Recent 
outbreaks of MERS-CoV infections have caused world health officials concern due to the 
potential for sustained person-to-person spread coupled with inadequately prepared 
healthcare systems (41). Further, current US military presence in the Middle East is 
concerning as military personnel are particularly susceptible to zoonotic infections due to 
increased stress and naïve immune systems. The mechanisms of CoV emergence are not 
understood, and no effective treatments or vaccines are available for CoV infections. 
Thus, is it essential to understand mechanisms of viral pathogenesis and differences in 
viral genomes that contribute to increased virulence.  
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Figure 1.1 Phylogeny of Coronaviridae 
The phylogeny of the family Coronaviridae is shown. Coronaviridae falls within the 
order of Nidovirales and is sub-classified into the genera α-, β-, γ-, and δ-CoV. The 6 
known human CoVs are indicated in red, and the BSL-2 model CoV, murine hepatitis 
virus, is indicated in blue. Modified from a drawing created by Eric Donaldson.  
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CoVs contain the some of the largest known positive strand RNA viral genomes, 
ranging from 27-32 kb. CoVs are spherical or pleomorphic enveloped particles 
containing positive strand RNA associated with a helical nucleocapsid. The envelope has 
club-shaped glycoprotein surface projections, termed spike, which resemble solar coronas 
(Figure 1.2). Thus, CoVs are named in reference to their characteristic corona 
morphology seen in electron micrographs (Figure 1.2B and C). CoV genomes are 
arranged similarly with a 5’ replicase gene, 3’ structural genes, and 3’ accessory genes. 
The encoded structural genes include hemagglutinin esterase (HE), if present, and all of 
the following: spike (S), small membrane (E), membrane (M), and nucleocapsid (N). 
Encoded accessory genes vary between virus strains. The replicase gene is translated as a 
polyprotein that is cleaved into 16 individual non-structural proteins (nsp) by encoded 
papain-like protease(s), which are domain(s) within nsp3, and the 3C-like protease 
(3CLpro, Mpro, nsp5) (Figure 1.2C) (42). The β-CoV murine coronavirus (MuCoV, 
MHV) has been highly studied as a model system to understand CoV replication, 
genetics, tropism, and pathogenesis (Figure 1.1). In fact, MHV represents a collection of 
virus strains that have been used to study pathogenesis the central nervous system, the 
liver, and the lung. MHV is also noted as one of the few animal models for the study of 
chronic demyelinating diseases such as multiple sclerosis (67). In the Denison lab, we use 
a strain of MHV, MHV-A59, as a model to study CoVs. The genome of MHV is 
indicated in Figure 1.2C.  
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Figure 1.2 Coronavirus Structure and Genome Organization 
A) Electron micrograph image of human coronavirus 229E (Courtesy CDC Public Health 
Image Library) showing distinct “corona” of spike proteins on membrane. B) Virion 
structure with spike protein indicated in grey, membrane protein indicated in light blue, 
and envelope protein indicated in yellow. Modified from a drawing created by Megan 
Culler-Freeman C) Genomic organization of MHV CoV. Polycistronic transcript is 
shown with genes indicated. Polyprotein 1a and 1ab (pp1a, pp1ab) translation products 
are shown with protease cleavage sites indicated by arrowheads.  
 
 
  
pp1a 
5 An     3 ORF 1a ORF 1b 2a Spike 4 5a E M N 
pp1ab 
1 
PLP1 PLP2 
N - 2 3 4 5 6 7 8 9-11 
- C 12 13 14 15 16 
A B 
C 
 7 
Coronavirus lifecycle 
Coronaviruses initiate cellular infection by receptor-mediated endocytosis. The CoV class 
I fusion S protein binds cellular receptors. Cellular receptors used by CoVs include 
carcinoembyronic antigen adhesion molecule 1 (CEACAM1) by MHV, aminopeptidase 
N by HCoV-229E, angiotensin-converting enzyme 2 (ACE2) by HCoV-NL63 and 
SARS-CoV, 9-O-acetylated sialic acid by HCoV-OC43, and dipeptidyl peptidase 4 
(DPP4) by MERS-CoV (47, 49, 68). Once endocytosed, viral nucleocapsid is released in 
the cytoplasm, and the message sense viral RNA is translated into the replicase 
polyprotein (pp1a or pp1ab) by host ribosomes (31, 33). Genomic replication occurs 
within replication complexes formed on modified endoplasmic reticulum (ER) 
membranes.  Nsps 3, 4, and 6 have been demonstrated to modify host ER membranes, 
resulting in double membrane vesicle (DMV) and convoluted membrane (CM) structures 
(Figure 1.3B) (3, 30, 66). The genome is replicated through a full-length negative sense 
RNA intermediate that is used as template for new positive sense progeny genomes.  
The 3’ end of the genome is replicated through subgenomic mRNAs, which are 
then translated into structural proteins (Figure 1.2B), HE, S, E, M, and N. The structural 
proteins are trafficked through the endoplasmic reticulum-Golgi intermediate 
compartment (ERGIC), where N protein encapsulates progeny genomes and virus 
assembly occurs. Progeny virions are released via non-lytic exocytosis pathways (Figure 
1.3B). Finally, extra S protein is transported to the cell membrane, where it can cause 
cells to fuse and form multinucleated giant cells, syncytia. This allows the virus to infect 
new cells while putatively avoiding host immune detection (Figure 1.3) (42).  
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Figure 1.3 Coronavirus Replication 
A) Model of coronavirus replication is shown. Briefly, the virus enters by receptor 
mediated endocytosis, the genome is translated and replication occurs at replication 
complexes on modified ER membranes, assembly occurs in the ERGIC, new virions 
emerge via non-lytic pathways, and syncytia formation likely occurs due to extra viral 
spike protein on the cell surface. Blue, green and red represent nsps 3, 4, and 6. Other 
colors indicate nsps 1, 2, 5, and 7-16. B) CM and DMV are indicated (left), virions in 
vesicles prior to egress (middle), and progeny virions exiting the cell (right). Scale bars 
represent 500 nm. Electron micrographs by Dia Beachboard, unpublished. 
  
√ !!
*! *!
*!
CM!
V!
V!
Nucleus 
ER 
ERGIC 
1. Entry 
2. Genome 
Translation 
and 
Replication 3. Assembly 
4. Egress 
5. Syncytia 
A 
B 
 9 
Coronavirus nsp5 protease structure 
The CoV genome is translated into polyproteins pp1a (486 kDa) and pp1ab (790 kDa), 
which are then cleaved into functional non-structural proteins by encoded proteases (13, 
20). One or two encoded papain-like protease(s) (PLpro, nsp3) process the N-terminal 
portions of pp1a and pp1ab, resulting in autoproteolytic cleavage and mature nsp1, nsp2, 
and nsp3 (22) (Figure 1.2). PLpro is considered papain-like due to a conserved Cys/His 
catalytic dyad and α/β fold (76). The C-terminal regions of pp1a and pp1ab are processed 
by nsp5 at 7 and 11 sites, respectively, resulting in mature nsp4-nsp16 as well as its own 
autoproteolytic cleavage (11, 24, 34, 45).  
Originally reported by Lu et. al., nsp5 is a 27 kDa protein composed of three 
domains.  Domain 1 (MHV residues 1 – 100 [D1]) and domain 2 (MHV residues 101 – 
199 [D2]) form a chymotrypsin-like fold with a His41 Cys145 catalytic dyad (Figure 
1.4A and B) (38-40). It has been demonstrated that mutation of Cys145 to Ala145 
(C145A) abolishes catalytic activity without altering folding (4, 5, 35, 62). CoV nsp5 
proteases are among the largest of their type, consisting of 300-306 amino acids, which is 
about 100 residues more than observed in picornavirus 3C protease homologs (76). The 
size discrepancy is due to an additional C-terminal domain, domain 3 (MHV residues 200 
- 303 [D3]) that is unique to CoVs (Figure 1.4B). This unique domain is an α-helical 
bundle required for replication (51, 64). It has been proposed that D3 mediates 
dimerization (Figure 1.4C), but the exact function remains to be elucidated (53, 54, 63). 
A conserved interdomain loop (IDL) (MHV residues 184 to 199) connects the domains 
1/2 to D3.  
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Cleavage of nsp5 substrates occurs most frequently after a conserved Gln (Q) in 
the P1 position, similar to picornavirus 3Cpro cleavage sites (Figure 1.4D) (39). The 
consensus nsp5 cleavage site among known CoVs is P2-LQ†(S/G/A/V)-P1’ (Figure 
1.4D) (10, 14, 76). Thus, CoV nsp5 proteases have functional and structural homology to 
picornavirus 3C proteases (51).  
The substrate-binding pocket is between D1 and D2, where the P1 residue of the 
substrate interacts with a conserved Tyr – x – His motif (Figure 1.4D). In MHV nsp5, the 
substrate-binding pocket is composed of Tyr161, Met162, and His163 (Figure 1.4A). 
Multiple groups have suggested that the His163 of this motif forms hydrogen bonds with 
the P1 Gln residue of substrate (19, 70).  
Studies suggest that nsp5 acts as a functional dimer, with the two monomers 
oriented perpendicular to one another (Figure 1.4C) (8, 36, 52, 69, 74). Although 
dimerization is required for nsp5 activity, studies suggest that N-terminal autoprocessing 
occurs via a monomeric form (6, 7). Further, in vitro studies suggest that only one 
monomer is catalytically active within the dimer (5). This activity loss has been attributed 
to the collapse of the oxyanion hole of the S1 substrate-binding site (Figure 1.4D) (61).  
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Figure 1.4 Nsp5 Structure and Functional Regions 
A) The two catalytic residues, His41 and Cys145, are shown in green. The substrate 
binding pocket, a conserved Tyr – x – His motif (yellow) binds the P1 residue (Gln) of 
substrate. B) A model of MHV nsp5 using HKU1 nsp5 structure is shown. Domain 1 
(red), domain 2 (blue), domain 3 (grey), and the catalytic dyad (green) are shown. C) 
Model of nsp5 in putative active dimer form. D) Canonical nsp5 substrate (green) binding 
to nsp5 protease (blue). Substrate binding pocket residues are indicated with “S” and 
substrate residues are indicated with “P.” Nsp5 catalytic dyad is indicated in red, and 
cleavage occurs after a Glu in the P1 position. (D Adapted form Grum-Tokars (2008) 
(21).)  
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Of the 6 known HCoVs, the crystal structure has been solved for nsp5 from 
SARS-CoV, HCoV-NL63, HCoV-229E, HCoV-HKU1, and MERS-CoV (unpublished) 
(2, 9, 32, 73). The crystal structure of nsp5 has also been solved for the γ-CoV infectious 
bronchitis virus (IBV) (70), the α-CoV transmissible gastroenteritis coronavirus (TGEV) 
(71), and the β-CoV BtHKU4. Despite primary sequence differences, with percent 
identities as low as 21% for HCoV-NL63 nsp5, the tertiary structure of nsp5 is highly 
conserved (20, 37, 59). Domains 1 and 2 exhibit high tertiary structure conservation 
while D3 is much more variable (Figure 1.5). The variability of D3 may be explained by 
the uniqueness of D3 to CoVs or the fact that D3 does not contain catalytic or substrate 
binding residues. Our lab has previously demonstrated the limitations and fitness costs of 
substituting nsp5 proteases from other CoVs into the MHV genome (59). Due to the 
structural and functional conservation of the CoV nsp5 chymotrypsin-like fold, it is likely 
that this genetic limitation is associated with the unique domain 3.  
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Figure 1.5 Nsp5 is Structurally Conserved 
Structural alignment of nsp5 proteases from SARS-CoV (blue), HCoV-HKU1 (red), 
HCoV-229E (orange), HCoV-NL63 (cyan), and IBV (green). The structure of MHV 
(black) was modeled on the structure of HCoV-HKU1 using Modeller. The percent 
identities of CoV nsp5 proteases with respect to MHV are shown in parenthesis.  
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Proteolytic processing in coronaviruses 
Nsp5 dimerization has been shown to be indispensable for trans- cleavage 
activity. Interestingly, Chen et. al. showed that Glu290 and Arg298, two residues known 
to contribute to the mature protease active dimer can be mutated to Arg and Glu, 
respectively. E290R and R298E mutants can both perform N-terminal autoprocessing, 
while the dimerization of mature protease and trans- cleavage activity were completely 
abolished (7). 
Several other studies have demonstrated the requirement of dimerization for 
enzymatic activity. For example, Lin et. al. demonstrated that deletion of Gln299 or 
Arg298 decreased enzymatic activity to 98-99% compared to wild type (WT). Decreased 
enzymatic activity correlated with an increase in the monomeric form of the enzyme by 
sedimentation assay. Further, analysis of nearby hydrogen bonding partners of Gln299 
and Arg298, Ser123 and Ser139, respectively, revealed a strong correlation between the 
enzyme activity loss and dimer dissociation (36).  
Zhong et. al. further elucidated the dimerization mechanism by solving the 
structure of the monomeric and dimeric forms of the nsp5 C-terminal domain alone 
(nsp5-C). They determined that the nsp5-C dimer structure is characterized by 3D 
domain swapping, in which the first helices of the two protomers are interchanged and 
each is encircled by four other helices from the other protomer (75). 
Numerous groups have reported models of nsp5 folding, dimerization and 
activity. As discussed above, nsp5 is active as a dimer, with only one monomer active 
within the dimer (7, 24, 34, 45). The immature form of nsp5 has proteolytic activity, with 
approximately 8-fold stimulation of activity by N-terminal cleavage, approximately 4-
 15 
fold stimulation by C-terminal cleavage, and 23-fold stimulation by the cleavage of both 
termini. Again, nsp5 autoprocessing is understood to occur in trans at the C-terminus (7, 
24, 34, 45). 
Chen et. al. proposed a model of nsp5 autoprocessing and dimerization, where 
two immature, folded nsp5 monomers approach one another and their D3s dimerize. This 
triggers movement of the N-termini into the substrate-binding pocket of the other 
monomer. Once N-terminal autoprocessing occurs, the monomers and N-termini assume 
their final conformation within the dimer. Next, the uncleaved C-terminus of one mature 
dimer can insert into an active site of another mature dimer. In the final step, the C-
terminus is processed in trans, resulting in the final mature nsp5 dimer observed in crystal 
structures of nsp5 proteases (Figure 1.6) (7). Once folding, stabilization, and dimerization 
of nsp5 have taken place, the protease processes viral polyproteins within replication 
complexes (Figure 1.6). This model suggests that we should only be able to find nsp4/5/6 
and nsp5/6 polyprotein intermediates, but data from our lab indicate that an additional 
nsp4/5 intermediate may also exist. Thus, the exact mechanism of nsp5 activity remains 
to be elucidated.  
Despite structural and functional conservation among known CoV nsp5 proteases, 
there is a strong genetic limitation to the capacity to swap the nsp5 protease between 
CoVs (59). The existence of this genetic barrier emphasizes the need to further 
understand structural determinants of nsp5 function. Our studies could uncover a 
functional determinant that could be targeted for broadly reactive small molecule 
protease inhibitors.  
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Figure 1.6 Model of Nsp5 Dimerization and Activity 
Model of nsp5 autoprocessing, dimerization, activity during infection. 1. CoV genome is 
translated as a polyprotein. 2. Nsp5 domains fold and associate to form an immature 
dimer. 3. Immature nsp5 dimer cleaves the nsp4-5 cleavage site in cis, liberating nsp4. 4. 
N-terminal portion of monomer assume mature positions away from the active site. 5. 
The nsp5-6 cleavage site is processed in trans, liberating nsp6. 6. Nsp5 dimer is in the 
final mature, active form. 7. Nsp5 dimer recognizes polyprotein cleavage sites 8. Nsp5 
activity occurs on ER membranes at replication complexes in order to liberate viral nsps 
for replication. Adapted from Chen et. al (2010) (7).  
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Active-site inhibitors of coronavirus nsp5 protease 
The lack of efficacious therapeutics or vaccines for CoV infections underscores the need 
to continue to develop CoV therapeutics. Nsp5 is a promising target for viral inhibition 
since its activity is required for viral replication. Several groups have reported the 
identification of nsp5 protease active site inhibitors that prevent viral replication (18, 19, 
25, 27, 29, 50). Due to the recent emergence of MERS-CoV, several groups have 
revisited this work, each suggesting that protease inhibition could lead to CoV 
therapeutics.  
 Kilianski et. al. reported an in vitro study on a MERS-CoV nsp5 inhibitor 
screening platform. The authors expressed MERS-CoV nsp5, and they used luciferase-
based biosensors to measure protease activity. The authors report the ability to perform 
both endpoint evaluation and live-cell imaging to profile protease activity. The authors 
evaluated a chloropyridine ester small molecule inhibitor, CE-5, within their platform and 
calculated an effective concentration 50% (EC50) of 12.5 µM against MERS-CoV nsp5 
(27). Previously, this compound was reported to have an inhibitory concentration 50% 
(IC50) against SARS-CoV nsp5 of 0.31±0.05 µM and an EC50 concentration of 24±0.9 
µM against SARS-CoV (18). Further, Agnihothram et. al. reported this compound to be 
effective at inhibiting Bat HKU-5 CoV and MERS-CoV replication during viral infection 
of cells by 100-fold at 24 h p.i. at 50 µM (1). These studies indicate the feasibility of 
developing a class of small molecule inhibitors that is broadly reactive against CoVs. 
Minimally, this work suggests that broadly reactive inhibitors against each CoV genus (α-
, β-, and γ-CoV) could be developed.  
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Summary 
Coronaviruses cause both acute and chronic upper-respiratory disease and lower-
respiratory tract illnesses. Both SARS-CoV and MERS-CoV are associated with severe 
febrile respiratory illness, pneumonia, and mortality. The mechanisms of HCoV 
emergence and pathogenesis are not understood, making it essential to continue to 
develop and evaluate broad-spectrum CoV replication inhibitors. Previous work has 
shown small molecule inhibitors to be effective at inhibiting nsp5. Thus, nsp5 is a proven 
target for viral inhibition since its activity is required for viral replication. In order to 
more effectively target nsp5 for viral inhibition, we must understand structural 
determinants of nsp5 protease function. Our work to understand nsp5 structure-function 
relationships in order to define novel regions within nsp5 for allosteric inhibition will be 
critical to developing viral therapeutics.  
The CoV nsp5 protease has evolved a unique modification to the chymotrypsin 
fold. It contains a chymotrypsin fold connected to a novel α-helical domain (D3) by a 16 
residue interdomain loop (IDL). Previous work has implicated D3 in substrate binding, 
trans-cleavage activity, and dimerization of protomers to form an active protease. 
Further, the IDL of equine arterivirus main protease (nsp4) contains putative hinge 
regions that are important for determining the timing and specificity of processing (65). 
Thus, we hypothesized that the novel third domain and IDL of CoV nsp5 protease have a 
unique, undefined function. To test this hypothesis, we probed interactions of residues 
spanning the Domain 2 (D2)/Domain 3 (D3) interface using our reverse genetics system 
and evaluation of polyprotein processing. We evaluated putative hinge regions within the 
IDL via alanine scanning mutagenesis and biochemical evaluation of mutants. This work 
 19 
combined with future studies may shed light on structural determinants of nsp5 protease 
function that could be targeted allosterically for protease inhibition.  
In addition to structure-function studies of nsp5, we tested and evaluated 9 small 
molecule nsp5 inhibitors of several classes for the ability to inhibit CoV replication. I 
evaluated covalent modifying inhibitors, non-covalent inhibitors, and peptide-like 
inhibitors of nsp5 that were previously biochemically validated. Further, I predict CoV 
nsp5 protease will mutate to escape inhibition by conserved intermolecular interactions. 
To test inhibitors and our hypothesis, I used firefly luciferase (FFL) reporter viruses to 
generate EC50 values based on change in reporter luminescence activity. I passaged WT 
virus in the presence of inhibitors to assess the potential for mutational escape. This work 
combined with future studies may shed light on CoV evolutionary mechanisms and 
phylogenetic relationships based on the similarities and differences observed in antiviral 
escape mutations between different nsp5 proteases. This work will also impact 
therapeutic design as detailed understanding of nsp5 function and the similarities and 
differences between various nsp5 proteases will be used to inform therapeutic design.  
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CHAPTER 2 :  
 
TO DEFINE STRUCTURAL DETERMINANTS WITHIN NSP5 CRITICAL TO 
PROTEASE FUNCTION AND DYNAMICS 
 
Introduction 
CoV nsp5 protease contains a novel α-helical domain (D3) connected to the 
chymotrypsin fold, D1/2, through a 16 residue IDL. Previous work from Stobart et. al. 
and others have implicated D3 and the IDL in the functionality of nsp5 (58). This work 
identified a number of residues within nsp5, which confer temperature-sensitivity, that 
are non-conserved among CoVs and can readily mutate to augment protease activity. 
When passaged at non-permissive temperatures, temperature-sensitive (ts) mutants 
S133A, V148A, and F219L were found to have developed secondary mutations that 
restored nsp5 activity. These secondary mutations included T129M, H134Y, H270HH, 
and E285V, in domains 2 and 3 (Figure 2.1) (58). No two of these residues are closer 
than 10 Å in distance based on a homology model of the MHV nsp5 structure. It was 
concluded that structurally distant, non-conserved residues are connected through tertiary 
structure to provide nodes of allosteric communication within the protease (Figure 2.1). 
Suel et. al. provide further support for networks of distant residues that confer allosteric 
communication within proteins (60).  
In equine arteritis virus (EAV), an arterivirus in the order Nidovirales, Aken et. al. 
described an 8 residue loop connecting the chymotrypsin fold of the nsp4 main protease 
to a novel C-terminal domain (CTD, D3). Structurally and functionally, the EAV nsp4 
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main protease is very similar to the CoV nsp5 main protease. The authors proposed that 
residues within this loop could be acting as a hinge region (HR) to facilitate the 
movement of the CTD. Crystal structures of EAV nsp4 have shown the CTD in one of 
four unique positions. It was concluded that residues within the HR control the spatial 
orientation of the CTD in order to regulate protease activity and the use of cofactors (65). 
The CoV nsp5 protease is structurally similar to EAV nsp4 with both a chymotrypsin-like 
fold and a unique C-terminal domain connected by a loop of amino acid residues. My 
work provides evidence that the CoV nsp5 IDL may contain determinants of protease 
function similar to the HR of EAV. Thus, I performed scanning mutagenesis on the CoV 
nsp5 IDL and domain 3 in order to identify these functional determinants.  
 
  
 22 
 
 
Figure 2.1 Distant Nsp5 Residues are Nodes For Allosteric Communication 
MHV nsp5 structure modeled on HKU1 nsp5 is shown with D1/2 in light grey, D3 in 
dark grey, and active site residues in green. Temperature-sensitive alleles (red) and 
suppressor alleles (orange) identified by C. Stobart et. al. (2012) are indicated (58). 
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IDL Scanning Mutagenesis 
To gain insight into structural determinants of nsp5 function, I performed scanning 
mutagenesis on each of the 16 residues of the IDL. I mutated each residue to an alanine, 
or I made more conservative mutations for less variable residues (Figure 2.2). For 
example, Asp187 and Gln192 are both 100% conserved across all CoV nsp5 sequences. 
Thus, I mutated those residues to glutamic acid and asparagine, respectively. I introduced 
additions and truncations at the IDL C-terminus. I expected that viruses with mutations at 
100%-conserved residues would not be recoverable. I also expected that mutations in 
variable regions of the IDL, which alter amino acid interactions, would result in 
debilitated or non-viable virus.  
 I ordered primers to introduce IDL mutations, additions, and truncations as listed 
in Table 5.1. I performed Quick Change PCR to introduce each mutation within MHV C 
fragment. Viruses were generated using the established reverse genetics system used by 
the Denison lab. Briefly, I ligated the 7 MHV fragments using T4 ligase. I in vitro 
transcribed ligated DNA and electroporated into baby hamster kidney-MHV receptor 
cells (BHK-MHVR). I then overlaid the electroporated BHK-MHVR cells onto delayed 
brain tumor cells (DBT) and monitored for signs of syncytia for a minimum of 3 days. If 
no cytopathic effects (CPE) were observed after two attempts, I extracted total cellular 
RNA in TRIzol reagent, performed reverse transcription-polymerase chain reaction (RT-
PCR) using primers for nsp5, and tested for the presence of virus. I then attempted to 
recover virus a third time. I recovered P184A, R186A, A188I, V190I, V191I, L193A, 
P194A, Q196A, and Y198A (Figure 2.2A). The nsp5 coding region was sequenced and 
no additional mutations were identified. The D187E, T199A, +199, +197-199, or Δ199 
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viruses were not recovered. I did not attempt to recover Tyr185, Gln189, Val195, and 
Asp197.  
 Of the 9 recovered viruses, several contained residues that are between 2.2 Å and 
2.7 Å from each other and could potentially interact via electrostatics to stabilize the IDL. 
This is interesting since electrostatic bonds, hydrogen bonds, and van der Waals forces 
are all potential bonding interactions that could occur at these distance ranges and such 
interactions are generally conserved to maintain protein structure. The residue Gln192 is 
2.2 Å from Arg186, 2.4 Å from Ala188, 2.7 Å from Val190. Residue Pro184 is 2.6 Å 
from Val195. And Pro194 is 2.5 Å from Tyr185 (Figure 2.2B – D). Further, Val190, 
Ala188, and Asp187 all have interacting distances between 3.3 Å and 4.3 Å suggesting 
that these interactions could be conserved to maintain structure and function. However, 
the residues themselves are variable among CoV nsp5 proteases. Many of the variable 
IDL residues are somewhat functionally conserved as hydrophobic/hydrophilic and 
acidic/basic. Several residues including residue 186 and 188 readily convert between 
acidic and basic amino acids across all CoV nsp5 sequences.  
 Among the unrecoverable viruses were truncations and additions at the C-terminal 
end of nsp5, mutation of the C-terminal threonine, and mutation of 100% conserved 
residues (Asp187 and Gln192). This suggests that precise positioning of D3 by the IDL 
either contributes to protein folding, stability, or function. Further, residues Asp187 and 
Gln192 are putative “Achilles’ heels” of the protease since they are /required for viral 
recovery. Additionally, Brett Case in the Denison lab recently discovered that DBT cells 
secrete low levels of interferon (personal communication). This may impact the recovery 
of extremely debilitated viruses since low levels of interferon may be enough to clear the 
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viral infection. It is possible that some unrecovered viruses may be recoverable if 
attempted in BHK-MHVR cells in the absence of DBT cells.   
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Figure 2.2 IDL Scanning Mutagenesis 
Alanine scanning mutagenesis was performed on residues 184-199 of the interdomain 
loop as indicated using Quick Change protocol (Stratagene). A) Domain 1 is indicated in 
red, domain 2 including the IDL is indicated in blue, and domain 3 is indicated in grey. 
The *indicates 100% conserved residue. Green indicates recovered virus. Red indicates 
unrecoverable virus. B) IDL residues indicated in rainbow scheme. C and D) Putative 
interacting IDL residues with distance between amino acids indicated in Å. 
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 To determine whether the substitutions alter virus replication, I infected DBT 
cells with WT-MHV as a control, P184A, V190I, V191I, Q196A, R186A, Y198A, and 
A188I at a multiplicity of infection (MOI) of 1 plaque-forming unit per cell (PFU/cell). 
Interestingly, all of the viruses displayed similar replication kinetics to WT-MHV (Figure 
2.3). WT-MHV replicated exponentially between 6 and 8 h p.i. and achieved peak titer at 
12 h p.i. Each mutant virus tested replicated indistinguishably from WT-MHV. This data 
indicates that any putative stabilizing interactions between residues across the IDL, as 
indicated in Figure 2.2, are not required for proper protease function. Further, the 
capacity of each mutant virus to replicate with kinetics similar to that of WT-MHV 
suggests that each protease is properly folded, selects substrates appropriately, and 
catalyzes peptide bond cleavages at a WT-like rate. However, further studies need to be 
performed to confirm protein folding and activity.  
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Figure 2.3 Replication Kinetics of IDL Mutant Viruses 
DBT cells were infected with indicated viruses at MOI=1 PFU/cell. Aliquots of 
supernatant were collected at indicated times post infection, and titers were determined 
by plaque assay. Error bars represent the standard error of the mean of three independent 
replicates performed in duplicate. 
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Mutagenesis of Domain 2-Domain 3 Interface Residues 
In addition to evaluating residues within the IDL, I wanted to evaluate residues spanning 
the D2/D3 interface for interactions that modulate activity. As indicated in Figure 2.4A, 
Arg131 (R131) of D2 and Asp286  (D286) of D3 are 3.5 Å apart while Gly109 (G109) of 
D2 and Asn203 (N203) of D3 are 2.2 Å apart. These distances are short enough that 
electrostatic interactions, hydrogen bonding, or van der Waals forces could occur 
between these residues. Additionally, N203, G109, R131, and D286 are all 100% 
conserved residues across CoV nsp5 proteases. To assess these putative interactions, I 
introduced the mutations indicated in Table 2.1. I was unable to recover any of the 
attempted mutants except for N203C. I recovered N203C with T111A as putative 
compensatory mutation. I then attempted to plaque purify the virus, but 2 separate plaque 
purifications resulted in additional, putative compensatory mutations. Plaque 1 contained 
N203C, T111A, and T129A, while plaque 2 contained N203C and T129A. I then 
passaged the virus 4 times in DBT cells. Both passage 3 (P3) and passage 4 (P4) 
contained N203C with T111A (Figure 2.4C).  
These results suggest that N203 interacts with either or both T129 and T111 
across the D2/D3 interface. Further, these results support work from Stobart et. al. who 
initially reported allosteric communication networks occurring within nsp5. Interestingly, 
these residues are within short enough distances from one another to interact directly as 
opposed to long-distance allosteric interaction. T129M was reported by Stobart et. al. as a 
compensatory mutation that arose when ts mutant viruses were passaged at non-
permissive temperatures (Figure 2.1) (58).  
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Figure 2.4 Domain 2- Domain 3 Interface Residues 
A and B) Putative interacting residue pairs spanning the domain 2 – domain 3 interface 
are indicated in red and purple. Catalytic residues are indicated in black. C) 
Compensatory mutations isolated in combination with N203C mutant virus are indicated 
in orange (T129A and T111A). N203 and G109 are indicated in purple.  
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Table 2.1 Domain 2 – Domain 3 Interface Residue Mutant Virus Recovery 
Mutation Status 
G109L Not Recovered (1x) 
G109C Not Attempted 
R131A Not Recovered (1x) 
R131K Not Recovered (1x) 
R131C Not Recovered (2x) 
N203A Not Recovered (1x) 
N203C Recovered with T129A and/or T111A 
D286A Not Recovered (1x) 
D286C Not Recovered (1x) 
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In order to test whether the substitutions and compensatory mutations alter virus 
replication, DBT cells were infected with WT-MHV as a control, N203C P0 
(N203C/T111A), N203C P4 (N203C/T111A), and N203C Plaque 2 (N203C/T129A) at 
MOI = 1 PFU/cell. Each mutant virus replicated with kinetics indistinguishable from 
WT-MHV (Figure 2.5). Previous work has shown T129 to be a residue capable of 
mutating under specific pressures in order to confer normal protease activity. Therefore, 
the WT-like replication kinetics of each N203C mutant virus suggests that T129A and 
T111A act as compensatory mutations.  
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Figure 2.5 Replication Kinetics of N203 Mutant Viruses 
DBT cells were infected with indicated viruses at MOI=1 PFU/cell. Aliquots of 
supernatant were collected at indicated times post infection, and titers were determined 
by plaque assay. Error bars represent the standard error of the mean of three independent 
replicates performed in duplicate. 
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Discussion and Future Directions 
Several mutations within the IDL resulted in genomes that could not be recovered as 
viruses, suggesting that these residues may be particularly important in protease structure, 
function, or folding. Interestingly, a number of the residues within the IDL were readily 
mutated resulting in no replication defects including Pro184 and Arg186. These residues 
were of particular importance since I thought they might contribute to IDL stabilization 
through inter-residue interactions. Further, the N203C substitution in D3 was only 
recovered in the presence of additional, putative compensatory mutations that arose in 
D2. This suggests that N203 may be required for protease function. This work also 
suggests that residues within the IDL and residues that span the D2/D3 interface 
communicate either directly or over long distances with residues of other domains and 
contribute to protease function. 
The recovered IDL mutant viruses should be evaluated for altered polyprotein 
processing by immunoprecipitation. If the IDL does in fact act as a hinge region to 
mediate selectivity and order of polyprotein processing, it is possible that different 
polyprotein intermediates could be identified. It would be necessary to compare 
polyprotein intermediates between mutant viruses and WT-MHV at multiple time points 
using antibodies to each MHV non-structural protein. For example, Aken et. al. identified 
altered concentrations of several non-structural proteins and partially processed 
polyprotein intermediates in their study of EAV nsp4 main protease (65). I would expect 
to see a similar result with our IDL mutant viruses if any of the engineered mutations 
alter function and substrate selection. A pulse-chase experiment with chase times 
between 15 minutes and 300 minutes followed by immunoprecipitation could be useful to 
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assess protein degradation versus diminished production. It would also be useful to assess 
any changes in timing of various polyprotein cleavages by monitoring polyprotein 
intermediates during pulse-chase. Further, competition assays between the mutant viruses 
and WT-MHV could be performed. If I saw strong differences in viral fitness, I would 
conclude that intervening, variable IDL residues do modulate protease function. If I saw 
similar fitness, I would conclude that the virus has evolved to allow large amounts of 
mutation in the IDL because maintenance of the few conserved residues and interactions 
are absolutely critical to protease function. 
Data obtained from experiments in cultured cells including replication kinetics, 
polyprotein processing, and pulse-chase radiolabeled translation will allow us to 
determine the kinetics of viral infection. However, it is important to determine the 
difference between binding effects vs. unfolding effects in mutant viruses. It will be 
essential to perform isothermal titration calorimetry (ITC) or fluorometry to determine if 
peptide substrates are still able to bind the mutant nsp5. ITC is commonly used in 
biochemistry laboratories to assess both binding affinity and thermodynamic parameters. 
Fluorometry could be used to evaluate binding using fluorescence resonance energy 
transfer (FRET), labeled peptide substrates available from Andrew Mesecar’s lab (Purdue 
University), or intrinsic protein fluorescence. Nuclear magnetic resonance (NMR) or a 
crystal structure would be needed for strong experimental evidence of peptide binding. In 
terms of folding, intrinsic protein fluorescence or circular dichroism (CD) can be used to 
determine if mutant nsp5 proteins are folding properly or unfolding. CD could also be 
used to determine ts effects of mutations if performed at a gradient of temperatures. This 
work could be performed in collaboration with the Mesecar lab. 
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Peptide-protein docking could be used to computationally identify or confirm 
residues mediating important interactions during polyprotein processing. This method 
involves docking short peptides into the modeled MHV nsp5 structure. The online server 
FlexPepDock (http://flexpepdock.furmanlab.cs.huji.ac.il/index.php) is an available 
resource to begin this sort of study, however, the online server is limited in 
resources/options. We could model each mutation in the IDL or spanning the D2/D3 
interface to identify structural perturbations once a peptide is docked in the active site. 
Biochemical and cellular data will improve these models. This work could be performed 
in collaboration with Jens Meiler’s lab at Vanderbilt University.  
In order to determine the how important IDL flexibility is for function, we could 
engineer several mutations into the IDL simultaneously. We would choose a group of 
mutations that made the IDL as rigid as possible as well as a group of residue that made 
the IDL as flexible as possible. We could also try to kink the IDL more by adding in Pro 
mutations at a number of residues. Finally, we could try to swap the IDL from a different 
CoV, such as MERS-CoV, into MHV nsp5 and attempt virus recovery. For each of these 
mutations and swaps within nsp5, we could perform computational, biochemical, and cell 
culture studies described above.  
I have identified residue N203 as an important mediator of nsp5 function since it 
is 100% conserved and the N203C substitution can only be recovered in the presence of 
putative compensatory mutations. It would be useful to model N203C, T129A, and 
T111A into the HKU1 nsp5 structure using Rosetta or Modeller to identify possible 
changes in interactions. We could reverse engineer each compensatory mutation into 
WT-MHV and assess replication kinetics, polyproteins processing, and protein 
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degradation. We could also attempt to recover G109, R131, and D286 mutants by reverse 
engineering putative compensatory mutations identified through Rosetta/Modeller 
modeling. Results from these studies and previous studies may suggest that conserved 
interactions across the D2-D3 interface in addition to interactions mediated by D187, 
Q193, and T199 maintain nsp5 structure-function.  
In addition to activity studies, we also would like to understand the dynamic 
movement of domains and the IDL during protease function.  The Electron Paramagnetic 
Resonance (EPR) method of site-directed spin labeling (SDSL) with double electron-
electron resonance (DEER) spectroscopy is an established biophysical technique that 
bridges the gap between protein structure and function. Spin labeling in conjunction with 
EPR spectroscopy can give insight into protein dynamics. EPR relies on SDSL where 
surface exposed residues along a protein are mutated to a cysteine and then complexed to 
a spin label (43). The most commonly used spin label is 1-oxyl-2,2,5,5-
tetramethylpyrroline-3-methyl-methanethiosulfonate (MTSSL). Quantitative 
measurements of spin label solvent accessibility and inter-label distances can be made 
with EPR. Deconvolution of EPR spectra allows determination of protein structure, 
topology, and packing. DEER is a relatively new, yet established, technique that allows 
long-range distance measurements (60Å- 80Å) between pairs of spin labels (16, 17, 26). 
It allows quantitative analysis of equilibrium dynamics and conformational changes. For 
example, DEER can be used to assess movement of secondary structures, flexible loops, 
and side chain movement when triggered. The readout from DEER spectroscopy is 
changes in a distance profile, P(r), which is the probability of distances (rav) between two 
spin labels (43).  
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 Figure 2.6A (bottom left) shows a scenario where a membrane protein converts 
from state A to state B. The distance distribution, P(r), clearly changes modes. In Figure 
2.6A (bottom right), the membrane protein is in equilibrium between states A and B 
where condition 1 may indicate the lack of a substrate/cofactor and condition 2 may 
indicate the presence of a substrate/cofactor that has triggered a shift in the 
conformational equilibrium. The DEER technique has been successfully employed by 
Gail Fanucci’s lab (University of Florida) in the study of Human immunodeficiency virus 
type 1 (HIV-1) protease dynamics (26). DEER could be used in the study of CoV nsp5 to 
understand functional dynamics of the IDL and D3. To perform this study, each solvent 
exposed cysteine residue on the protease would need to be mutated to alanine without 
altering protease folding or function. The cysteine residues of MHV nsp5 are indicated in 
cyan in Figure 2.6B. Once mutated, any remaining or added solvent exposed cysteine 
residues in the protease would be labeled by SDSL and EPR spectroscopy would be 
performed. The addition of nsp5 inhibitors or universal substrates would be added to 
trigger a conformational change in the protein that can be monitored by DEER. This 
work could be performed in collaboration with Hassane Mchaourab’s lab at Vanderbilt 
University.  
 Taken together, these studies will allow us to answer questions regarding the role 
of the CoV nsp5 IDL and D3 during protease function. IDL mutagenesis and polyprotein 
processing in addition to biochemical and computational studies will help us to identify 
residues that may act as determinants of protease function. This data can be used to 
inform which residues to spin label and then probe via DEER experiments. Finally, 
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DEER spectroscopy will provide us with the necessary link between 
structural/computational data and functional/cell culture data.  
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Figure 2.6 Double Electron-Electron Resonance (DEER) Approach 
A) DEER readout gives changes in distance profile with or without substrate or inhibitor. 
P(r) = probability of distance between two spin labels (distance distribution) from rav. 
Graphs indicate model is sampling either state A or is in equilibrium between sates A and 
B. Courtesy of H. Mchaourab (43). B) Cysteine residues of nsp5 that may need to be 
mutated for DEER experiments are indicated in cyan, active site residues are indicated in 
green. 
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CHAPTER 3 :  
 
PLATFORM TO ASSESS EFFICACY OF NSP5 INHIBITORS AND PATHWAYS OF 
ANTIVIRAL RESISTANCE 
 
Introduction 
Coronaviruses (CoVs) cause a number of human diseases, most notably Severe Acute 
Respiratory Syndrome and the more recent Middle East Respiratory Syndrome. These 
zoonotic pathogens are of importance since they exhibit pandemic potential and high 
mortality rates. The mechanisms of CoV emergence are not understood, making it 
essential to develop broadly effective therapeutics to treat future emergent human CoVs. 
CoVs have positive-sense RNA genomes that are translated into polyproteins that are 
processed into mature proteins by encoded proteases including the main protease (Mpro, 
nsp5). Nsp5 is required for CoV replication, and it is responsible for 11 polyprotein 
cleavage events. Thus, it is a key target for the design of both active-site inhibitors and 
allosteric inhibitors. Mechanisms of protease function and dynamics identified by IDL 
and D2/3 interface analysis will guide inhibitor design in addition to concepts such as cell 
penetration and activity of side-products. . 
Key obstacles to developing nsp5 inhibitors are (1) the inability to culture and test 
most CoVs and (2) antiviral resistance. Therefore, I have generated a novel 
biotechnological platform for rapid testing of biochemically-validated inhibitors and 
screening for new inhibitors. I generated fusions of firefly luciferase protein (FFL) to 
nsp2 for each of two previously reported MHV chimeric viruses. These chimeric viruses 
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contain nsp5 from HCoV-HKU1 (H5-MHV) or HCoV-OC43 (O5-MHV) and have been 
previously shown to have replication kinetics similar to WT-MHV (59). Our lab has 
previously demonstrated that FFL-nsp2 fusions do not alter viral replication kinetics, and 
we have shown that luciferase activity can be used to quantitate protein translation and 
genome replication (15).  
Interestingly, we have been unable to recover chimeric viruses containing nsp5 
protease substitutions from viruses outside of subgroup 2a β-CoV (Figure 1.1). Stobart et. 
al. reported that substitutions into the MHV background of subgroup 2a β-CoV nsp5 
proteases containing up to 84% sequence identity (Figure 1.5) to MHV nsp5 resulted in 
fitness costs (59). Our lab was unable to recover chimeric viruses containing nsp5 
proteases from the following CoVs in the MHV background: HCoV-229E, HCoV-NL63, 
BtCoV-HKU4, and SARS-CoV. In addition, I have been unable to recover MERS-CoV 
nsp5 protease in an MHV or SARS-CoV background. I propose that the inability to 
recover chimeric viruses outside of particular subgroups is due to the divergence of 
function and regulation of protease activity. Stobart et. al. suggested that conservation of 
intermolecular residue interactions may be most closely associated with members of the 
same subgroup (59). Thus, it may be most feasible to generate nsp5 inhibitors that are 
broadly effective across specific CoV genera. For example, the covalent modifying 
inhibitor, CE-5 (GRL-001-13S) has been shown by several labs to be effective across the 
β-CoV genus.  
The Mesecar lab at Purdue University has developed a series of chloro-pyridyl 
ester nsp5 active site inhibitors, among which CE-5 (GRL-001-13S) has shown particular 
promise for broad reactivity. Kilianski et. al. reported an EC50 of 12.5 µM against MERS-
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CoV nsp5 (27). Previously, this compound was reported to have an IC50 against SARS-
CoV nsp5 of 0.31±0.05 µM and an EC50 concentration of 24±0.9 µM against SARS-CoV 
(18). Further, Agnihothram et. al. reported this compound to be effective at inhibiting 
BtCoV-HKU-5 and MERS-CoV 100-fold at 50 µM (1). Further, our studies using 
chimeric reporter viruses containing nsp5 proteases from HCoV-HKU1 and HCoV-OC43 
show EC50 values ranging between 1.5 µM – 5 µM. Thus, this inhibitor, CE-5, is broadly 
effective against the β-CoV genus.  
I generated and used chimeric reporter viruses to determine EC50 values for nsp5 
inhibitors. Preliminary data suggests that inhibitors are specifically inhibiting the nsp5 
protease since our assay shows differential sensitivity between chimeric viruses to several 
tested inhibitors including GRL-002-13S. The only difference between chimeric viruses 
is the protease itself, so differences in log reductions should reflect protease inhibition. I 
also passaged viruses in the presence of inhibitors in an effort to identify pathways of 
antiviral resistance. I anticipate that this system will prove useful for optimizing inhibitor 
design, resulting in enhanced therapeutic potential. 
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Experimental Design 
In order to test compounds, I needed a platform comprised of i) a reporter molecule and 
ii) multiple nsp5 proteases. Both were separately available resources in the lab, so I 
combined them to generate chimeric nsp5 reporter viruses. I generated N-terminal FFL 
fusions to nsp2 using previously established cloning techniques (15) and our reverse 
genetics system for MHV (72). Our lab has previously demonstrated that luciferase 
activity from MHV containing FFL fused to the N-terminal portion of nsp2 (MHV-FFL) 
can be directly used to quantitate virus replication. Further, virus replication directly 
depends on nsp5 protease activity. Thus, I used luciferase activity to measure nsp5 
inhibition. I fused FFL to the N-terminal portion of nsp2 within H5-MHV and O5-MHV 
resulting in H5-MHV-FFL and O5-MHV-FFL (Figure 3.1). Each chimeric virus contains 
normal MHV nsp5 cleavage sites excluding the nsp4-5 and nsp5-6 cleavage sites. The 
nsp4-5 cleavage site was designed to contain MHV P sites and HKU1/OC43 P’ sites, 
while the nsp5-6 cleavage sites contain HKU1/OC43 P sites and MHV P’ sites. Both 
viruses were readily recovered in DBT cells at 37oC with similar CPE to that of WT-
MHV. Once recovered, I used TRIzol (Invitrogen) to extract total cellular RNA. I used 
RT-PCR to generate amplicons that span FFL and nsp5 coding regions. These amplicons 
were Sanger sequenced and confirmed to contain intact regions with no additional 
mutations.  
 
 
 
  
 45 
 
 
Figure 3.1 Engineered Nsp5 Chimeric Reporter Viruses 
Nsps 1-16 are indicated. Protease cleavage sites are indicated by arrowheads above the 
polyprotein. FFL reporter was engineered as a fusion with nsp2 (yellow). Chimeric nsp5 
proteases are indicated in red (HCoV-HKu1) and green (HCoV-OC43).  
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In order to assess the chimeric viruses for utility in testing nsp5 inhibitors, I first 
needed to test viral replication and luciferase activity. DBT cells were infected with 
indicated viruses (Figure 3.2A) at MOI = 1 PFU/cell. At each time point indicated, 
supernatants were collected and titered by plaque assay. Once supernatants were 
sampled, cells were harvested and tested for luciferase activity. WT-MHV began 
exponential replication between 6 – 8 h p.i. and reach peak titer at 12 h p.i. (Figure 3.2A). 
Each virus replicated indistinguishable from WT-MHV, indicating that both chimeric 
nsp5 proteases and FFL-nsp2 fusions do not alter the timing or efficiency of viral 
replication.  
 To assess luciferase activity, I sampled infected cells at multiple time-points p.i. 
at the same time I measured viral replication kinetics. WT-MHV lacking an FFL protein 
was incorporated as a negative control. Briefly, cells infected at MOI = 1 PFU/cell were 
washed at desired time points with phosphate buffered saline (PBS), and the appropriate 
amount of reporter lysis buffer (Promega) was added. Cells were frozen at -80oC until the 
luciferase assay was performed. To measure RLU, cells were warmed to ambient 
temperature and transferred into a 96-well plate. The luciferase assay reagent (Promega) 
was suspended according to directions, and the reagent was added and activity read by a 
Veritas luminometer. MHV-FFL showed 5 logs of luciferase activity measured in relative 
light units (RLU), and it reached peak luciferase activity at 12 h p.i (Figure 3.2B). Both 
H5-MHV-FFL and O5-MHV-FFL displayed luciferase activity indistinguishable from 
MHV-FFL. Additionally, luciferase activity directly correlated with replication kinetics 
with peak luciferase activity and peak viral titer both occurring at 12 h p.i.  
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 In order to verify the FFL-nsp2 fusion, I performed an immunoprecipitation (IP) 
experiment on cells infected with each chimeric reporter virus. I infected DBT cells at 
MOI = 10 PFU/cell, radiolabeled with [35S]-Met/-Cys media, harvested cell lysates, then 
IP with rabbit polyclonal α-MHV nsp2 antibody. As indicated in Figure 3.2C, WT-MHV, 
H5-MHV, and O5-MHV each show a band at 65-kDa, indicative of native nsp2, while 
MHV-FFL, H5-MHV-FFL, and O5-MHV-FFL lacked the 65-kDa band and had an 
additional band at 100-kDa. This band is consistent in size with the FFL-nsp2 fusion. 
Together, the data in Figure 3.2 indicates that our chimeric reporter viruses were 
successfully engineered and recovered with replication kinetics and luciferase activity 
indistinguishable from WT-MHV (or MHV-FFL).  
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Figure 3.2 Characterization of Chimeric Reporter Viruses 
A) Chimeric reporter viruses have same replication kinetics as WT-MHV. DBT cells 
were infected with indicated viruses at MOI=1 PFU/cell. Aliquots of virus were taken at 
indicated times p.i. and titers were determined by plaque assay. B) FFL activity of 
chimeric reporter viruses correlates with replication kinetics. DBT cells were infected 
with indicated viruses at MOI=1 PFU/cell. Aliquots of virus were taken at indicated 
times p.i. and RLU were determined using Luciferase Assay (Promega). FFL relative 
light units (RLU) are indicated. Error bars represent the standard error of the mean of 
three independent replicates performed in duplicate. C) Chimeric reporter viruses contain 
nsp2-FFL fusion. DBT cells were infected with indicated viruses at MOI = 10 PFU/cell, 
and radiolabeled with [35S]-Met/-Cys media. Cell lysates were IP with rabbit polyclonal 
α-MHV nsp2 antibody, run on an SDS-PAGE gel, and imaged by autoradiography.  
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 Next, I sought to validate our chimeric reporter viruses as a platform to test nsp5 
inhibitors. In collaboration with the Mesecar lab, I obtained a series of biochemically 
validated nsp5 active-site inhibitors. These inhibitors, listed in Table 3.1, include several 
covalently modifying chloropyridyl ester-derived compounds identified by Ghosh et. al. 
(18), noncovalent acetamide-derived inhibitors (25), and peptide-like inhibitors. I 
assessed the cellular toxicity of each of these compounds up to 100 µM in rat lung 
epithelium (L2) cells using a CellTiter-Glo assay (Promega) in a Veritas luminometer. At 
100 µM, no inhibitor reduced cell viability by more than 15% (Figure 3.3). I then tested 
each inhibitor for reduction in RLU, which is indicative of reduction in viral replication 
(15). Briefly, I incubated cells infected with MHV-FFL, H5-FFL, or O5-FFL with 
biochemically validated nsp5 active-site inhibitors at concentration ranges from 0 µM - 
100 µM. At 10 h p.i., I harvested infected cells, and tested for luciferase activity. GRL-
001-13S (also CE-5) reduced RLU and therefore viral replication at low µM 
concentrations for each viral chimera tested (Figure 3.3). However GRL-002-13S was 
much less effective at reducing viral replication for each virus. This compound has 
differential effects on each viral chimera tested, with EC50 values ranging from 6 – 200 
µM, demonstrating that the inhibitors specifically act on nsp5 and not the MHV 
backbone. Estimates of EC50 values for all compounds are listed in Table 3.1. Of the 
compounds tested, GRL-001-13S and RWB exhibited the lowest EC50 values for each 
viral chimera (Table 3.1). This data demonstrates that these viruses can be used to rapidly 
screen for nsp5 inhibitors against OC43, HKU1, and MHV. This is useful since HKU1 
and OC43 are otherwise extremely difficult to cultivate and therefore test for protease 
inhibition.  
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Figure 3.3 Small Molecule Inhibitor Assay 
A) L2 cells were treated with indicated concentrations of inhibitors. RLU were 
determined using Promega CellTiter-Glo Assay. Percent cell viability was calculated 
relative to DMSO treated cells. Error bars represent the standard error of the mean of 
three independent replicates. B and C) L2 cells were infected with the indicated FFL 
viruses at MOI=1 PFU/cell, and treated with indicated concentrations of GRL-001-13S 
(B) or GRL-002-13S (C). RLU were determined using Promega Luciferase Assay. Fold 
change in RLU was calculated relative to mock treated infected cells. Points represent 
average of three independent replicates. 
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Table 3.1 Compounds Tested for Nsp5 Inhibitory Activity 
Compound Structure IC50 *(µM) 
(SARS) 
IC50 
(µM) 
(MHV) 
IC50 
(µM) 
(HKu1) 
IC50 
(µM) 
(OC43) 
EC50 
(µM) 
(MHV) 
EC50 
(µM) 
(H5) 
EC50 
(µM) 
(O5) 
Ki (µM) 
(MERS) 
GB8  
 
27 10.9 9.6 24 100-200 25-50 100-
200 
ND 
GRL-001-13S 
 
 
0.31± 0.05 ND ND ND 3-5 2-3 1.5-3 ND 
GRL-002-13S 
 
 
ND ND ND ND 25-50 50-
200 
6-12.5 9.9±2.6 
GRL-006-13S 
 
 
ND ND ND ND 30-70 25-
100 
70-200 4.7±0.6 
GRL-007-13S 
 
ND ND ND ND 15-50 12-50 0.1-50 9.0±2.3 
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Compound Structure IC50 
(µM) 
(SARS) 
IC50 
(µM) 
(MHV) 
IC50 
(µM) 
(HKu1) 
IC50 
(µM) 
(OC43) 
EC50 
(µM) 
(MHV) 
EC50 
(µM) 
(H5) 
EC50 
(µM) 
(O5) 
Ki (µM) 
(MERS
) 
RFM 
 
 
ND 3.4 19.0 0.49 30-100 3-6.5 25-125 ND 
RWB 
 
 
1.5* 7.4 9.8 8.3 12 4.5 0.35 ND 
UIC-0310 
 
 
ND ND ND ND 100+ 100+ 70-150 3.6±0.8 
UIC-0314  
 
ND ND ND ND 25-50 12.5-
30 
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Discussion and Future Directions 
Based on my data, my method of evaluating nsp5 inhibitors represents a platform 
for rapid EC50 determination. My dose response curves show saturability and several logs 
of luciferase activity. Additionally, my concentration curves show differential effects 
between various nsp5 proteases. This indicates that reduction in RLU and thus viral 
replication in the presence of nsp5 inhibitor is directly due to nsp5 inhibition and not an 
off-target effect. Further, this platform provides us the ability to test inhibitors of nsp5 
proteases from CoVs that are not readily cultivatable.  
My data and previous work from our lab has demonstrated that nsp5 is likely 
highly co-evolved with the rest of the genome in largely unidentified ways. Specifically, 
while we were able to generate chimeric viruses by exchange of nsp5 into the MHV 
genome from closely related β-CoVs, we could not recover chimeric MHV expressing 
nsp5 from more distantly related β-CoVs (SARS-CoV, MERS-CoV) or α-CoVs (HCoV-
229E, HCoV-NL63).  In order to more broadly test inhibitors and investigate the genetic 
relationships among nsp5 proteases of diverse CoVs, I propose that a series of viruses 
from each CoV genus subgroup could be used as a backbone to generate nsp5 chimeras. 
For example, BtCoV-HKU5 could be used as an isogenic background to generate nsp5 
chimeras from MERS-CoV and BtCoV-HKU4 (Error! Reference source not found.). 
his would be feasible since our collaborators at the University of North Carolina Chapel 
Hill in the Ralph Baric lab have recently developed a reverse genetics system for BtCoV-
HKU5, thus, it is readily cultivatable (1). HCoV-229E could be used as an isogenic 
background to put nsp5 proteases from NL63, BtCoV-HKU2, and BtCoV-HKU8 (Error! 
eference source not found.). Volker Thiel’s lab of the University of Berne, Switzerland, 
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has an established reverse genetics system for cultivation and study of HCoV-229E (23). 
These chimeras would be useful since they would make testing for inhibitors of many 
uncultivable CoVs feasible. They would also allow us to use our platform to quickly 
assess for broad reactivity of small molecule inhibitors.  
In an effort to assess the potential for antiviral resistance, I passaged WT-MHV 
four times in the presence of EC50 (5 µM) GRL-001-13S. I extracted viral RNA, RT-PCR 
amplified nsp5, and sequenced across the nsp5 region by Sanger sequencing. No 
mutations were identified within nsp5. While passaging the virus in the presence of drug, 
there was a delay in CPE followed by a rapid increase in CPE at 12-16 h p.i. This may 
indicate that the virus overcame the initial inhibition or that the drug was effective but 
degraded over time. Further, cells may not take up the drug readily, or it may precipitate 
out of solution. Future experiments could use temperature dependent 1H NMR to assess 
molecule stability and degradation. This passage experiment should be repeated using 
higher concentrations of inhibitor, up to EC99, in order to identify resistance mutations. 
Once we have isolated anti-viral resistance mutations, we could reverse engineer the 
mutations into each chimeric reporter virus and perform a luciferase assay to confirm an 
increase in EC50 values. Biochemical studies could also be performed to evaluate 
inhibitory concentration 50% values (IC50). We expect to find differences in antiviral 
resistance mutations based on the protease under inhibition. Knowing potential regions 
for compensation could improve the design of small molecule inhibitors that the virus 
cannot escape. Additionally, this data could inform methods of protease intramolecular 
communication as well as modes of functional and genetic divergence.  
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CHAPTER 4 :  
 
SUMMARY AND IMPLICATIONS 
 
This work has described a series of experiments designed to elucidate the mechanism of 
nsp5 activity in order to inform de novo inhibitor design. Several mutations within the 
IDL resulted in unrecoverable viruses, suggesting that these residues may be particularly 
important in protease function or folding. Conversely, several residues within the IDL 
were readily mutated resulting in no replication defects. Further, I was unable to recover 
N203C alone, suggesting that the 100% conserved N203 residue in D3 is likely to 
contribute to protease function. This work has shown that residues within the IDL likely 
interact with proximal residues as well as engaging in long distance communication 
across protease domains. Our studies to understand the structure-function relationships of 
CoV nsp5 proteases are of particular importance since they may reveal regions of the 
protease critical to function that may be targeted for allosteric inhibition.  
In addition to elucidating structure-function relationships of CoV nsp5 proteases, 
I have developed a platform to test inhibitors during infection as opposed to in vitro. This 
platform is useful since it provides us a way to rapidly quantitate viral replication via 
luciferase activity. It also provides us the ability to test inhibitors of nsp5 proteases from 
CoVs that are not readily cultivatable. We hope to develop an even broader platform, 
containing nsp5 chimeras for each CoV genus subgroup with nsp2-FFL fusions. A 
platform with this breadth would allow us to test new protease inhibitors for broad 
reactivity. It would also allow us to quickly evaluate nsp5 protease targeted drugs against 
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newly emergent zoonotic CoVs. Further, our efforts to generate nsp5 protease chimeras 
will help us to understand the evolution of nsp5 function and relationships to other 
replicase proteins. This, in turn, might identify novel residues or functional regions that 
are conserved across all CoVs, which could be targeted for allosteric inhibition by de 
novo design.   
A common problem with antiviral therapy is antiviral resistance. We expect that 
CoVs will mutate specific sets of variable residues within nsp5 in order to evade protease 
inhibition and promote viral replication. Although we cannot prevent antiviral resistance 
mutations from arising during nsp5 active-site inhibition, we can preemptively isolate 
resistance mutations and study them. Our plan to passage viruses in the presence of nsp5 
inhibitors in order to develop resistance mutations will allow us to understand modes of 
communication within the protease. This will allow us to iteratively develop better 
active-site inhibitors or even de novo design allosteric inhibitors that prevent 
intermolecular protease communication.  
It is critical that we develop several strategies to treat CoV infections as new 
HCoVs continue to emerge and cause severe human disease and mortality. We do not 
understand the zoonotic mechanisms by which HCoVs have emerged into the human 
population, thus, we are unable to predict or prevent future HCoV emergence. However, 
we can prepare platforms and approaches that are widely applicable to CoV genera in 
order to be prepared for future emergent disease. Data obtained from this and future 
studies will (i) define the role of the novel third domain and interdomain loop of nsp5, 
which connects the catalytic fold to the third domain, during substrate selection and 
catalytic activity, and (ii) develop novel inhibitors of nsp5 that exploit the functional 
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regions and activity of nsp5. Results from these studies will inform antiviral and vaccine 
development with an emphasis on developing a broadly applicable inhibitor screening 
platform and identifying broadly reactive small molecule protease inhibitors.   
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CHAPTER 5 :  
 
MATERIALS AND METHODS 
 
WT-MHV, Cells and Antibodies 
Recombinant MHV A59 (GenBank accession number AY910861) virus was used 
as WT-MHV for all experiments. Delayed brain tumor (DBT) cells, baby hamster kidney 
(BHK) cells, and rat lung epithelium (L2) cells were grown in Dulbecco’s modified Eagle 
medium (DMEM; Gibco) supplemented with 10% fetal bovine serum, 1% HEPES, 1% 
penicillin/streptomycin and 0.1% Amphotericin B (complete DMEM). Media for the 
BHK-MHV receptor (MHVR) cells was supplemented with G418 (Mediatech) at 
0.8mg/ml to maintain selection of MHVR. Rabbit polyclonal antibodies were used for 
immunoprecipitation directed at the viral nonstructural protein nsp5 (B3-VU6).  
 
Mutagenesis 
In order to introduce substitutions into nsp5, the MHV reverse genetics system was used. 
Briefly, the MHV genome is divided into seven plasmids, and nsp5 is located in plasmid 
pCR-XL-pSMART C. Nucleotides 9556-11510 are in fragment C. Substitutions were 
introduced into the C fragment using Quick Change (Stratagene) PCR mutagenesis, and 
the primers listed in Table 5.1. Changes to the manufacturer’s protocol include the use of 
PFU turbo and the following PCR conditions: initial denaturation at 95°C for 2 min, 
followed by 16 cycles of denaturation at 95°C for 30 sec, annealing at temperatures 
dependent on the primers for 1 min, and extension for 10 min at 72°C. All C fragment 
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plasmids containing mutations in nsp5 were sequenced to ensure that PCR amplification 
did not introduce additional changes in the coding region.  
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Table 5.1: Mutagenesis Primers 
Primer Name Sequence Purpose 
P184A sense 5'-GAACTTTTATGGTGCATATAGAGATGCGAAG-3' Mutagenesis for P184A 
P184A antisense 5'-CTTCGCATCTCTATATGCACCATAAAAGTTC-3' Mutagenesis for P184A 
Y185A sense  5'-TATGGTCCCGCGAGAGATGCG-3' Mutagenesis for Y185A 
Y185A antisense  5'-CGCATCTCTCGCGGGACCATA-3' Mutagenesis for Y185A 
R186A sense 5'-GTACAACTTGCGCATCAGCATAGGGACCATAAAAG-3' Mutagenesis for R186A 
R186A antisense 5'- CTTTTATGGTCCCTATGCTGATGCGCAAGTTGTAC -3' Mutagenesis for R186A 
D187E sense 5'-CCCTATAGAGAGGCGCAAGTT-3' Mutagenesis for D187E 
D187E antisense 5'-AACTTGCGCCTCTCTATAGGG-3' Mutagenesis for D187E 
A188I sense 5'- GCAATTGTACAACTTGAATATCTCTATAGGGAC -3' Mutagenesis for A188I 
A188I antisense 5'- GTCCCTATAGAGATATTCAAGTTGTACAATTGC -3' Mutagenesis for A188I 
Q189A sense 5’-CAGGCAATTGTACAACGGCCGCATCTCTATAGGG-3’ Mutagenesis for Q189A 
Q189A antisense 5’-CCCTATAGAGATGCGGCCGTTGTACAATTGCCTG-3’ Mutagenesis for Q189A 
V190I sense 5'- GAACAGGCAATTGTACGATTTGCGCATCTCTATAGG -3' Mutagenesis for V190I 
V190I antisense 5'- CCT ATA GAG ATG CGC AAA TCG TAC AAT TGC CTG TTC -3' Mutagenesis for V190I 
V191I sense 5'- CTGAACAGGCAATTGGATAACTTGCGCATCTC -3' Mutagenesis for V191I 
V191I antisense 5'- GAGATGCGCAAGTTATCCAATTGCCTGTTCAG -3' Mutagenesis for V191I 
Q192N sense 5'-GATGCGCAAGTTGTAAACTTGCCTGT-3' Mutagenesis for Q192N 
Q192N antisense 5'-GCGTATAATCCTGAACAGGCAAGTTT-3' Mutagenesis for Q192N 
L193A sense 5'- GTATAATCCTGAACAGGGGCTTGTACAACTTGCGC -3' Mutagenesis for L193A 
L193A antisense 5'- GCGCAAGTTGTACAAGCCCCTGTTCAGGATTATAC -3' Mutagenesis for L193A 
P194A sense 5'-GTTGTACAATTGGCGGTTCAGGATGATTATAC-3' Mutagenesis for P194A 
P194A antisense 5'-GTATAATCATCCTGAACCGCCAATTGTACAAC-3' Mutagenesis for P194A 
V195I sense 5’-CTGCGTATAATCCTGGATAGGCAATTGTACAAC-3’ Mutagenesis for V195I 
V195I antisense 5’-GTTGTACAATTGCCTATCCAGGATTATACGCAG-3’ Mutagenesis for V195I 
Q196A sense 5'-CAATTGCCTGTTGCAGATTATACGCAG-3' Mutagenesis for Q196A 
Q196A antisense 5'-CTGCGTATAATCTGCAACAGGCAATTG-3' Mutagenesis for Q196A 
D197A sense 5'-CAGTCTGCGTATATGCCTGAACAGGCAATTG-3' Mutagenesis for D197A 
D197A antisense 5'-CAATTGCCTGTTCAGGCATATACGCAGACTG -3' Mutagenesis for D197A 
Y198A sense 5'-CCTGTTCAGGATGCGACGCAGACTGT-3' Mutagenesis for Y198A 
Y198A antisense 5'-AACAGTCTGCGTCGCATCCTGAACAG-3' Mutagenesis for Y198A 
T199A sense 5'-CCTGTTCAGGATTATGCACAGACTGT-3' Mutagenesis for T199A 
T199A antisense 5'-AACAGTCTGTGCATAATCCTGAACAG-3' Mutagenesis for T199A 
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Primer Name Sequence Purpose 
Δ199 sense 5'- GCTACAACATTAACAGTCTGATAATCCTGAACAGGCAATTGTAC 
AAC -3' 
Mutagenesis for Δ199 
Δ199 antisense 5'- GTTGTACAATTGCCTGTTCAGGATTATCAGACTGTTAATGTTGTA GC -3' Mutagenesis for Δ199 
+197-199 sense 5'- GCTACAACATTAACAGTCTGCGTATAATCCGTATAATCCTGAAC AGGCAATTG -3' Mutagenesis for +197-199 
+197-199 
antisense 
5'- CAATTGCCTGTTCAGGATTATACGGATTATACGCAGACTGTTAAT 
GTTGTAGC -3' 
Mutagenesis for +197-
199 
+199 sense 5'- GCTACAACATTAACAGTCTGCGTCGTATAATCCTGAACAGGCAA TTG -3' Mutagenesis for +199 
+199 antisense 5'- CAATTGCCTGTTCAGGATTATACGACGCAGACTGTTAATGTTGTA GC -3' Mutagenesis for +199 
R131A sense 5'-CTTTATGGTATGGCTACTCGCAAGCGTAACATGGAAG-3' Mutagenesis for R131A 
R131A antisense 5'- CTTCCATGTTACGCTTGCGAGTAGCCATACCATAAAG -3' Mutagenesis for R131A 
R131K sense 5'-CTTTATGGTATGGCTACTTTTAAGCGTAACATGGAAG-3' Mutagenesis for R131K 
R131K antisense 5'- CTTCCATGTTACGCTTAAAAGTAGCCATACCATAAAG -3' Mutagenesis for R131K 
R131C sense 5'-CTTTATGGTATGGCTACTGCAAAGCGTAACATGGAAG-3' Mutagenesis for R131C 
R131C antisense 5'- CTTCCATGTTACGCTTTGCAGTAGCCATACCATAAAG -3' Mutagenesis for R131C 
D286A sense 5'- CTTGGTGTCAGCTCTGCTTCAAGCACACAAC -3' Mutagenesis for D286A 
D286A antisense 5'- GTTGTGTGCTTGAAGCAGAGCTGACACCAAG -3' Mutagenesis for D286A 
D286C sense 5'-CTTGGTGTCAGCTCGCATTCAAGCACACAAC-3' Mutagenesis for D286C 
D286C antisense 5'- GTTGTGTGCTTGAA GCGAGCTGACACCAAG -3' Mutagenesis for D286C 
G109L sense 5'-GTACAGTAAATGTCTCTAGAGGCTTAACAACACC-3' Mutagenesis for G109L 
G109L antisense 5'- GGTGTTGTTAAGCCTCTAGAGACATTTACTGTAC -3' Mutagenesis for G109L 
G109C sense 5'-GTACAGTAAATGTCTCGCAAGGCTTAACAACACC-3' Mutagenesis for G109C 
G109C antisense 5'- GGTGTTGTTAAGCCTTGCGAGACATTTACTGTAC -3' Mutagenesis for G109C 
N203A sense 5'-CATAAAGCCAAGCTACAACTGCAACAGTCTGCGTATAATC-3' Mutagenesis for N203A 
N203A antisense 5'- GATTATACGCAGACTGTTGCAGTTGTAGCTTGGCTTTATG -3' Mutagenesis for N203A 
N203C sense 5'-CATAAAGCCAAGCTACAACGCAAACAGTCTGCGTATAATC-3' Mutagenesis for N203C 
N203C antisense 5'- GATTATACGCAGACTGTTTGCGTTGTAGCTTGGCTTTATG -3' Mutagenesis for N203C 
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Virus Recovery 
Viruses containing the nsp5 mutations were generated using the reverse genetics 
system for MHV-A59 described by Yount et al. (72) and modified by Denison et al. (12) 
and Sparks et al (56). Briefly, the MHV-A59 genome is divided into seven cDNA 
fragments, which were digested using the appropriate restriction enzymes. These digested 
fragments were then ligated at 16 °C overnight before the DNA was purified, in vitro 
transcribed and electroporated into BHK-MHVR cells along with N gene transcripts. 
Electroporated cells were co-cultured with DBT cells and incubated at 37 °C until 
cytopathic effects were observed. The cytopathic effect see in MHV-infected cells is the 
formation of multinucleated giant cells (syncytia formation). The virus produced from 
electroporated cells (passage 0, P0) was passaged onto uninfected DBT cells to generate a 
P1 stock virus that was used for all experiments. The P0 virus was sequenced across the 
nsp5 gene to ensure that no additional mutations were present. If the in vitro transcribed 
genome did not produce virus on the first attempt, virus assembly was attempted at least 
two additional times.  
 
RT-PCR and Sequencing 
Total intracellular RNA was isolated using TRIzol (Invitrogen) and the 
manufacturer’s protocol. Viral RNA was then reverse transcribed using Superscript III 
(Invitrogen) and random hexamers (Roche). The nsp5 coding sequence was amplified by 
PCR using primers complementary to 10158 to 10177 (sense) and 11783 to 11799 
(antisense).  The nsp5 amplicons generated were directly Sanger sequenced to analyze 
retention of the engineered mutations and absence of additional mutations. 
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Viral replication Assay 
DBT cells were infected with either WT or nsp4 mutant viruses at an MOI of 1 
PFU/cell and absorbed for 30 min. Cells were then washed twice with PBS, media was 
replaced, and cells were incubated at 37°C. Supernatants were sampled from 1 hour to 24 
h post infection (p.i.) and viral titers were determined by plaque assay, as previously 
described (28).     
 
Radiolabel of viral proteins and protein immunoprecipitation 
DBT cells were infected at an MOI of 10 PFU/cell or mock infected. At 4 h p.i., 
the medium was replaced with DMEM that lacks cysteine and methionine and 
supplemented with 20 µg/ml actinomycin D (ActD; Sigma). At 5 h p.i., [35S]-
Methionine/-Cysteine ([35S]-Met/-Cys) was added to the cells and monitored for CPE. 
When cells were 90-100% involved in CPE, lysates were harvested in lysis buffer (1% 
NP-40, 0.5% sodium deoxycholate, 150 mM NaCl, and 50 mM Tris, pH 8.0). Lysates 
were centrifuged at 6,000X g for 3 min to remove nuclei. Viral proteins were 
immunoprecipitated in a total volume of 1ml with 0.6 mg of Protein A-Sepharose beads 
(Sigma), 200ul lysate, 1:250 dilution of polyclonal nsp5 antisera, and a protease inhibitor 
cocktail (Roche) in lysis buffer. After an overnight incubation, immunoprecipitated 
proteins were pelleted by centrifugation at 12,000 x g for 1 min. Protein-bead conjugates 
were then washed in low salt lysis buffer (lysis buffer with 150mM NaCl), high salt lysis 
buffer (Lysis buffer with 1M NaCl) and low salt lysis buffer. Samples were then 
resuspended in 2x SDS protein sample buffer, heated to 70°C for 10 min. Proteins were 
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resolved by SDS-PAGE gel electrophoresis on 4-12% Bis-Tris polyacrylamide gels 
(Invitrogen) and imaged by autoradiography. A full range rainbow ladder (GE 
Healthcare) and 14C ladder (PerkinElmer LAS) were used as molecular weight standards. 
 
Luciferase assay for nsp5 inhibition 
DBT cells were infected at MOI = 1 PFU/cell and absorbed for 30 minutes in 96-well 
plates. Nsp5 inhibitors were diluted in 1:2 serial dilutions at 50X concentration. Drug was 
added to wells with cells and complete DMEM (3 replicates each) resulting in 1X 
concentration of drug, 2% DMSO, and 2% fetal bovine serum. At 10 h p.i., cells were 
washed with PBS, and 100 µL of reporter lysis buffer (Promega) was added. Cells were 
frozen at -80oC until the luciferase assay was performed. To measure RLU, cells were 
warmed to ambient temperature. The luciferase assay reagent (Promega) was suspended 
according to directions, and the reagent was added and activity read by a Veritas 
luminometer. RLU raw data was normalized to untreated, infected wells and log 
transformed. Error bars represent standard error of the mean (SEM).  
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